share_log

Evogene Q2 Revenue Grows 131%, Here Is What You Need To Know

Benzinga Real-time News ·  Aug 31, 2022 11:32

Evogene Ltd.(NASDAQ:EVGN) (TASE: EVGN) Q2 2022 revenue was $312,000, an increase of 131% compared to $135,000 in the same period the previous year. Revenues were primarily due to the initial sales ofLavie Bio'sThrivusproduct (previously branded asResult) and sales ofCanonicproducts in the Israeli market.

Q2 2022 Financial Highlights

  • Net loss was $9.8 millionin comparison to a net loss of $6.9 million in the same period in the previous year.

  • R&D expensesfor the quarter, which are reported net of non-refundable grants received, were$5.4 million, in comparison to $5.0 million in the same period the previous year. The increase...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment